Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
September 30, 2026 106.69M
June 30, 2026 106.67M
March 31, 2026 104.89M
December 31, 2025 73.33M
September 30, 2025 33.19M
June 30, 2025 33.19M
March 31, 2025 33.19M
December 31, 2024 30.17M
September 30, 2024 30.17M
June 30, 2024 30.17M
March 31, 2024 30.17M
December 31, 2023 30.10M
September 30, 2023 30.10M
June 30, 2023 30.10M
March 31, 2023 30.10M
December 31, 2022 30.10M
September 30, 2022 28.64M
June 30, 2022 30.02M
March 31, 2022 29.40M
December 31, 2021 27.74M
September 30, 2021 17.50M
June 30, 2021 17.47M
March 31, 2021 16.75M
December 31, 2020 16.33M
September 30, 2020 16.19M
Date Value
June 30, 2020 15.85M
March 31, 2020 14.94M
June 30, 2019 9.745M
March 31, 2019 7.745M
December 31, 2018 7.441M
September 30, 2018 3.138M
June 30, 2018 3.138M
March 31, 2018 3.137M
December 31, 2017 3.136M
September 30, 2017 3.136M
June 30, 2017 3.132M
March 31, 2017 3.01M
December 31, 2016 3.009M
September 30, 2016 3.009M
June 30, 2016 3.009M
March 31, 2016 3.005M
December 31, 2015 3.000M
September 30, 2015 2.754M
June 30, 2015 2.695M
March 31, 2015 2.687M
December 31, 2014 2.684M
September 30, 2014 2.193M
February 28, 2014 1.425M
September 30, 2013 3.149M
August 31, 2013 1.425M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Talphera, Inc. 51.95M
Journey Medical Corp. 28.23M
ANI Pharmaceuticals, Inc. 22.90M
Corcept Therapeutics, Inc. 109.36M
Veru, Inc. 17.05M